The effect of exogenous sex hormones on the risk of breast cancer has been shown for some compounds but for other compounds it is under detailed investigation. This study, as part of a quadruple of articles reviewing the consequences of using sex hormones in women with various breast conditions, discusses the prescription of non-oral hormonal contraceptives and miscellaneous exogenous steroid hormones.
Introduction
Because of the association of breast cancer with [1] [2] [3] [4] [5] [6] female sex hormones , prescribing hormonal combinations in women especially in those harboring a disorder in the breast usually goes with hesitation and uncertainty. In order to answer some questions that physicians have in this regard, four sequential articles have been written discussing the prescription of different hormonal compounds in various We aimed to find valid data about the effects of miscellaneous hormones on the breasts. Because of interesting relevant literature about the effects on male breasts, we also searched and entered related data. We carried out a comprehensive search in Google Scholar and PubMed by using combinations of these keywords: "benign breast", "breast cancer", "conjugated estrogen", cyproterone, "ethinyl estradiol", etonogestrel, fibroadenoma, fibrocystic, finasteride, levonorgestrel, "male breast", medroxyprogesterone, and "progesterone implant". We extracted data from all pertinent works including cohort studies, clinical trials and reviews. We also browsed valid clinical guidelines including the International Agency for Research on Cancer (IARC), Monographs on the Evaluation of Carcinogenic Risks to Humans, the guidelines of the Society of Family Planning (SFP), the US Medical Eligibility Criteria for Contraceptive Use by the Centers for Disease Control and Prevention (CDC), and the US Selected Practice Recommendations for Contraceptive Use. All pertinent information was extracted from these references.
Results and Discussion
The approval of the injectable form of depotmedroxyprogesterone acetate (DMPA) as a contraceptive method has taken a long gradual course from its synthesis in 1963 to its use in more than 100 9 countries now . This lag was partly due to the probability of increasing the risk of breast cancer, which is still a matter of debate. However, while some studies have shown an approximate 2.2-fold 10, 11 increased risk of breast cancer due to DMPA , this association was shown to stop after discontinuation [11] [12] [13] [14] of the hormone, or not to existo. Thus, in addition to the general population, contraception using DMPA is permitted in women with benign breast disorders and even in those with psitive family history (FH) of breast cancer. Nevertheless, its use is contraindicated in patients with breast cancer, and considering the 15, 16 theoretical hazards, in survivors of the disease.
Progesterone Releasing Intrauterine Devices

Methods
Depot-medroxyprogesterone acetate acetate (DMPA), progesterone implants, cyproterone acetate, finasteride and spironolactone.
Intrauterine devices (IUDs) are used for longacting reversible contraception (LARC). Some types of commonly-used IUDs are those that release 15, 16 Levonorgestrel, or LNG-IUDs.
Despite the hormonal basis, levonorgestrel reaches very low 17 levels in the serum of women who use these IUDs.
Several large-scale studies have assessed the risk of breast cancer in women who use LNG-IUDs. They [18] [19] [20] [21] did not show an increased risk , except for one research derived from a Finnish registry which Different formulations containing synthetic estrogens or progesterone, although mostly used as OCPs or for HRT, are sometimes used for the treatment of hormone-related conditions such as abnormal uterine bleeding, menstrual irregularity, endometriosis, or hirsutism. However, the effects on the risk of breast cancer and on benign breast diseases have not been studied specifically for this purpose. For example, medroxyprogesterone in the oral form as tablets, megestrol acetate and dydrogesterone are commonly used for the treatment of menstrual disorders. Megestrol acetate has been studied for this purpose in breast cancer survivors, and also as an appetite stimulator for reversing cachexia in patients with metastatic breast cancer. These works generally yielded positive results, but the effects on the prognosis [29] [30] [31] [32] [33] [34] of cancer have not been investigated. The effects of dienogest on the breast tissue when consumed for the treatment of endometriosis have been explored in a study. All patients had significant decrease of breast 35 size and improvement of mastopathic changes.
Contraceptive implants
Non-contraceptive, non-HRT exogenous oral estrogen and progesterone compounds
Suggestions for the use of progesterone and estrogen compounds for the treatment of the mentioned gynecologic disorders in women with different breast conditions can be deducted from recommendations for OCPs as discussed in the first 8 article of these series and HRT as addressed in the 7 second article . They are demonstrated in table 1. 22 revealed an unexpectedly higher risk. Therefore, according to SFP and CDC recommendations, LNG-IUDs should not be offered to women with present or [15] [16] [17] previous breast cancer , with the probable exception of breast cancer survivors on tamoxifen, where LNG-IUDs might counteract proliferative 15, 16, [23] [24] [25] effects of tamoxifen on the endometrium. Use of these devices for contraception in women with benign diseases of the breasts and in patients with positive FH of breast cancer is recommended.
One of the LARC methods consists of implanting flexible rods containing and gradually releasing progestins. These are easily planted under the skin of the arm or removed whenever needed. The etonoge- 15, 16, 26, 27 strel implant is the most widely used method.
Studies investigating the association of contraceptive implants with breast cancer risk are scarce. One study with a small sample size derived no increased 14 risk , while an ethnic-based research showed a significant rise in the risk of breast cancer in users of 28 progesterone implants. Data of both studies should be considered with caution. Meanwhile, implants are not recommended as a method of contraception in breast cancer patients or survivors, while their use in benign breast disorders and women with positive FH 15, 16 is allowed.
Exogenous hormones and breast disease
Finasteride is an anti-androgen which functions by counteracting the action of 5αreductase. It is mostly used in the treatment of prostatic hyperplasia, androgenic alopecia in women, and sometimes in 43 hirsutism. While increased risk of male breast cancer has been attributed to finasteride in previous 49, 50 studies , this has not been confirmed in two recent 5 1 , 5 2 works.
Up to the present time, specific contraindication in women with breast disorders have not been defined.
Cyproterone acetate is a synthetic derivative of hydroxyprogesterone, which has a relatively high antiandrogenic as well as some antigonadotropic 41, 42 effects.
It is usually used as part of the management of menstrual disorders and hirsutism, or 43 contraception. It has also been used in prostate 42, 44 cancer.
One of its minor side effects is breast 45 discomfort. While drugs with estrogenic or progestronic properties are sometimes administered in intractable advanced metastatic breast cancer in women, cyproterone acetate has not proved effective in this 46 setting. On the other hand, two studies have demonstrated beneficial effects for this compound in 47, 48 advanced cases of male breast cancer.
Cyproterone acetate Finasteride
Cyproterone acetate is occasionally administered alone for the management of menstrual issues or hirsutism, but probable adverse effects on breast cancer risk, and also on benign breast disorders have not been studied in that setting. Therefore, the same recommendations for progesterone-only oral contraceptive pills can be followed for this medicine 8 too.
It is interesting that while these compounds are considered to have stimulatory effects on hormone receptor-positive breast cancer, they paradoxically can have beneficial effects on advanced, hormone- [36] [37] [38] [39] [40] resistant cases of breast cancer.
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Therefore, this category of compounds seems an alternative for the treatment of some menstrual disorders when breast cancer is the concern.
Spironolactone One of the common usages of this group of drugs is in the treatment of hormone receptor-positive premenopausal breast cancer, where they are 60 administered in conjunction with tamoxifen or 61 aromatase inhibitors , or for the preservation of 62, 63 ovarian function at the time of chemotherapy.
In conclusion, most non-oral hormonal methods of contraception and other available hormone compounds prescribed for the treatment of hormonal disorders are safe for temporary use, except for women with breast cancer, for whom analogues of gonadotropin-releasing hormone may be considered a safe hormonal prescription.
None.
Analogues of gonadotropin-releasing hormone (GnRH) bind competitively to central GnRH receptors in the pituitary gland. They are among the pharmacological treatments for the treatment of 57 58, 59 menorrhagia and the premenstrual syndrome.
Gonadotropin-releasing hormone Analogues
Spironolactone is an aldosterone antagonist with anti-androgenic effects that is commonly used for the 43 treatment of hirsutism. Although its potential for increasing male or female breast cancer has been put forward in earlier studies because of some case reports 53, 54 or series , the association is not confirmed by other 55, 56 works.
Until now, specific contraindication in women with breast disorders have not been defined. 
